The topic of developing therapeutic proteins includes a range of approaches for expressing prospective candidates in support of R&D endeavors. The following white paper provides information on the introduction of Samsung Bioloigcs' latest innovation, S-CHOsient™ –– a transient gene expression platform, which accelerates drug discovery and reduces cost when compared with traditional stable pools while simultaneously speeding up drug discoveries. Read more

The therapeutic implications of structural variants

In the field of therapeutic protein development, researchers can employ various methods to express their candidate protein for different stages of research and development. Two primary approaches are transient expression and stable clone expression, each with its own advantages and limitations. Stable clonal cell lines, used for GMP clinical and commercial manufacturing, have high protein yields through several stages of screening; however, developing the final cell lines takes considerable time. In contrast, transient expression offers a rapid solution for early discovery, process development, and screening of large protein libraries. 

Faster drug development with a transient expression platform 

To support the degree of developability insight and potential for ultimate commercialization demanded by modern drug development, Samsung Biologics has established a novel transient gene expression platform called S-CHOsient™. The S-CHOsient™ transient expression platform offers a faster and more cost-effective solution for early drug discovery compared to traditional stable pool production. This technology delivers high-quality protein in just weeks, ideal for clients with strict timelines. 

This transient expression platform supports multiple phases of drug development, including:

• Rapid production
• Early drug discovery
• Seamless CDO transition
• Preliminary data generation